v3.26.1
Consolidated Statements of Changes in Equity - USD ($)
$ in Thousands
Total
Common Shares [Member]
Additional Paid-In Capital [Member]
Retained Earnings [Member]
Accumulated Other Comprehensive Income (Loss) [Member]
Treasury Stock [Member]
Non-Controlling Interest [Member]
Common Stock Outstanding [Member]
Balance at Beginning of Period at Dec. 31, 2024 $ 252,318 $ 470 $ 109,547 $ 144,862 $ (5,769) $ (2,537) $ 5,745  
Balance at Beginning of Period at Dec. 31, 2024   46,966,868           46,826,820
Balance at Beginning of Period at Dec. 31, 2024           (140,048)    
Stock-based compensation 4,697   3,216     $ 1,481    
Stock-based compensation (shares)           79,200   79,200
Non-controlling interest contribution 19           19  
Dividends paid (938)     (938)        
Net income (loss) attributable to Core Laboratories Inc. 10,738     10,482     256  
Interest rate swaps, net of income taxes (302)       (302)      
Pension and other postretirement benefit plans, net of income taxes 114       114      
Repurchase of common stock (4,761)         $ (4,761)    
Repurchase of common stock (shares)           (369,230)   (369,230)
Balance at End of Period at Jun. 30, 2025 $ 261,885 $ 470 112,763 154,406 (5,957) $ (5,817) 6,020  
Balance at End of Period at Jun. 30, 2025   46,966,868           46,536,790
Balance at End of Period at Jun. 30, 2025           (430,078)    
Cash Dividends per Share $ 0.02              
Balance at Beginning of Period at Mar. 31, 2025 $ 253,938 $ 470 113,574 144,239 (5,886) $ (4,427) 5,968  
Balance at Beginning of Period at Mar. 31, 2025   46,966,868           46,702,192
Balance at Beginning of Period at Mar. 31, 2025           (264,676)    
Stock-based compensation 539   (811)     $ 1,350    
Stock-based compensation (shares)           72,230   72,230
Non-controlling interest contribution 19           19  
Dividends paid (469)     (469)        
Net income (loss) attributable to Core Laboratories Inc. 10,669     10,636     33  
Interest rate swaps, net of income taxes (129)       (129)      
Pension and other postretirement benefit plans, net of income taxes 58       58      
Repurchase of common stock (2,740)         $ (2,740)    
Repurchase of common stock (shares)           (237,632)   (237,632)
Balance at End of Period at Jun. 30, 2025 $ 261,885 $ 470 112,763 154,406 (5,957) $ (5,817) 6,020  
Balance at End of Period at Jun. 30, 2025   46,966,868           46,536,790
Balance at End of Period at Jun. 30, 2025           (430,078)    
Cash Dividends per Share $ 0.01              
Balance at Beginning of Period at Dec. 31, 2025 $ 272,208 $ 470 110,245 172,662 (5,806) $ (11,585) 6,222  
Balance at Beginning of Period at Dec. 31, 2025   46,966,868           46,095,379
Balance at Beginning of Period at Dec. 31, 2025 871,489         (871,489)    
Stock-based compensation $ 5,934   5,267     $ 667    
Stock-based compensation (shares)           55,214   55,214
Non-controlling interest contribution 0           0  
Dividends paid (920)     (920)        
Net income (loss) attributable to Core Laboratories Inc. 5,045     5,167     (122)  
Interest rate swaps, net of income taxes 14       14      
Pension and other postretirement benefit plans, net of income taxes 114       114      
Repurchase of common stock $ (3,626)         $ (3,626)    
Repurchase of common stock (shares) 266,493         (266,493)   (266,493)
Balance at End of Period at Jun. 30, 2026 $ 278,769 $ 470 115,512 176,909 (5,678) $ (14,544) 6,100  
Balance at End of Period at Jun. 30, 2026   46,966,868           45,884,100
Balance at End of Period at Jun. 30, 2026 1,082,768         (1,082,768)    
Cash Dividends per Share $ 0.02              
Balance at Beginning of Period at Mar. 31, 2026 $ 275,144 $ 470 115,221 171,413 (5,754) $ (12,464) 6,258  
Balance at Beginning of Period at Mar. 31, 2026   46,966,868           46,048,268
Balance at Beginning of Period at Mar. 31, 2026           (918,600)    
Stock-based compensation 902   291     $ 611    
Stock-based compensation (shares)           50,544   50,544
Non-controlling interest contribution 0           0  
Dividends paid (460)     (460)        
Net income (loss) attributable to Core Laboratories Inc. 5,798     5,956     (158)  
Interest rate swaps, net of income taxes 19       19      
Pension and other postretirement benefit plans, net of income taxes 57       57      
Repurchase of common stock $ (2,691)         $ (2,691)    
Repurchase of common stock (shares) 214,712         (214,712)   (214,712)
Balance at End of Period at Jun. 30, 2026 $ 278,769 $ 470 $ 115,512 $ 176,909 $ (5,678) $ (14,544) $ 6,100  
Balance at End of Period at Jun. 30, 2026   46,966,868           45,884,100
Balance at End of Period at Jun. 30, 2026 1,082,768         (1,082,768)    
Cash Dividends per Share $ 0.01